(605077)"Zhejiang Huakang Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 605077 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates a significant decline in profit and earnings compared to the same period last year, with total revenue and net profit both experiencing substantial decreases. The company attributes these declines to increased competition and changes in sales strategy, particularly in the liquid product segment. The report also includes unaudited financial statements and highlights the company's commitment to transparency and accuracy in its disclosures.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Huakang Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huakang Pharmaceutical
- (605077)"Zhejiang Huakang Pharmaceutical Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
- Announcement on Lifting of Restrictions and Listing of Shares for the Second Lifting Period of the Reserved Grant under the 2023 Restricted Share Incentive Plan
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Shareholding Reduction Plan by Shareholder Holding More Than 5% of the Shares
- Announcement on Progress in Providing Guarantee Limit for Wholly-owned Subsidiary
Later from Zhejiang Huakang Pharmaceutical
All Zhejiang Huakang Pharmaceutical news releasesFollow Zhejiang Huakang Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huakang Pharmaceutical